Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-003536-30 | EudraCT Number | ||
| 2012-R8 | Other Identifier | CPP | |
| A120316-72 | Other Identifier | Afssaps | |
| 912140 | Other Identifier | CNIL |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to test the efficacy of low-dose aspirin (160 mg/day), given bedtime and started early during pregnancy (≤ 15 +6 weeks of gestation) in nulliparous pregnant women selected as "high-risk" by the presence of a bilateral uterine artery notch and/or bilateral uterine artery PI ≥ 1.7 during the first trimester ultrasound scan (11-13+6 weeks), to prevent the occurrence of pre-eclampsia or small for gestational age at birth.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Aspirin | Experimental | Aspirin 160 mg per day |
|
| Placebo | Placebo Comparator | Placebo 160 mg per day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aspirin | Drug | Aspirin, 160 mg per day until 34 weeks of gestation |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Preeclampsia (diagnosed per ACOG criteria) and small for gestational age at birth (≤5th percentile on customized growth curves) | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Small for gestational age at birth (≤5th percentile on customized growth curves) | women will be followed for the duration of pregnancy, an expected average of 25 to 30 weeks | |
| Pre-eclampsia (ACOG criteria) requiring delivery before 34 weeks | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mode of delivery (vaginal or cesarean) | women will be followed for the duration of pregnancy, an expected average of 25 to 30 weeks | |
| Mode of anesthesia for delivery | women will be followed for the duration of pregnancy, an expected average of 25 to 30 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Franck PERROTIN, MD-PhD | University Hospital, Tours | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service de Gynécologie-Obstétrique, Groupe Hospitalier Pellegrin, CHRU de Bordeaux | Bordeaux | 33000 | France | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22986844 | Background | Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther. 2013;33(1):16-27. doi: 10.1159/000341712. Epub 2012 Sep 13. | |
| 23004922 | Background | Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int. 2013 Mar;30(1-2):260-79. doi: 10.3109/07420528.2012.717455. Epub 2012 Sep 24. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo, 160 mg per day until 34 weeks of gestation |
|
| Severe pre-eclampsia (ACOG criteria) | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Perinatal death (22 weeks of gestation to 7 days postnatal) | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Pre-eclampsia (ACOG criteria) | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Adverse effects of treatment | women will be followed for the duration of pregnancy and postpartum, an expected average of 26 to 31 weeks |
| Service de Gynécologie-Obstétrique, HFME, Hospices Civils de Lyon |
| Bron |
| 69677 |
| France |
| Service de gynécologie-obstétrique, Polyclinique du PARC | Caen | 14052 | France |
| Service de Gynécologie-Obstétrique, Hôpital d'Estaing, CHU de Clermont-Ferrand | Clermont-Ferrand | 63003 | France |
| Service de gynécologie-obstétrique, Hôpital Couple Enfant, CHRU de Grenoble | Grenoble | 38043 | France |
| Cabinet Mosaïque Santé | La Chaussée-Saint-Victor | 41260 | France |
| Service de gynécologie-obstétrique, CHR Le Mans | Le Mans | 72037 | France |
| Service de Gyénécologie-Obstétrique, Hôpital Jeanne de Flandre, CHRU de Lille | Lille | 59037 | France |
| Service de Gynécologie-Obstétrique, Hôpital Arnaud de Villeneuve, CHRU de Montpellier | Montpellier | 34295 | France |
| Service de gynécologie-obstétrique, Hôpital Mère-Enfant, CHRU de Nantes | Nantes | 44093 | France |
| Service de gynécologie-obstétrique, Polyclinique de l'Atlantique | Nantes | 44819 | France |
| Service de Gynécologie-Obstétrique, Hôpital Carémeau, CHRU de Nîmes | Nîmes | 30029 | France |
| Service de Gynécologie-Obstétrique, Hôpital Porte Madeleine, CHR d'Orléans | Orléans | 45032 | France |
| Centre de dépistage PRIMA FACIE, Hôpital Necker, APHP | Paris | 75014 | France |
| Service de Gynécologie-Obstétrique, Hôpital Paule de Viguier, CHU de Toulouse | Toulouse | 31059 | France |
| Service de Gynécologie-Obstetrique, Centre Olympe de Gouges, CHRU de Tours | Tours | 37044 | France |
| Service de gynécologie-obstétrique, Maison de la Femme de la Mère et de l'Enfant, CHU de Fort de France | Fort-de-France | 97261 | Martinique |
| 18634131 | Background | Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008 Aug;32(2):138-46. doi: 10.1002/uog.5402. |
| 36260615 | Result | Diguisto C, Le Gouge A, Marchand MS, Megier P, Ville Y, Haddad G, Winer N, Arthuis C, Doret M, Debarge VH, Flandrin A, Delmas HL, Gallot D, Mares P, Vayssiere C, Sentilhes L, Cheve MT, Paumier A, Durin L, Schaub B, Equy V, Giraudeau B, Perrotin F; Groupe de Recherche en Obstetrique et Gynecologie (GROG). Low-dose aspirin to prevent preeclampsia and growth restriction in nulliparous women identified by uterine artery Doppler as at high risk of preeclampsia: A double blinded randomized placebo-controlled trial. PLoS One. 2022 Oct 19;17(10):e0275129. doi: 10.1371/journal.pone.0275129. eCollection 2022. |
| ID | Term |
|---|---|
| D011225 | Pre-Eclampsia |
| ID | Term |
|---|---|
| D046110 | Hypertension, Pregnancy-Induced |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001241 | Aspirin |
| ID | Term |
|---|---|
| D012459 | Salicylates |
| D062385 | Hydroxybenzoates |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
Not provided
Not provided